Medical News

RSS

Compugen reports revenues of $125,000 for first-quarter 2010

Compugen Ltd. today reported financial results for the first quarter ending March 31, 2010.

27 Apr 2010

First Edition: April 27, 2010

Today's headlines focus on the details of health reform that continue to emerge -- including states' reactions to high risk pools and questions about the sweeping expansion of Medicaid.

27 Apr 2010

Pharmacological suppression of nonsense mutations effective in treating genetic defects

Genetic mutation can disrupt the way human cells make proteins, which in turn leads to inherited disease. David Bedwell, a professor in the University of Alabama at Birmingham (UAB) Department of Microbiology, says scientists are closer than ever to producing drugs that fix this disrupted-protein pathway and drastically improving treatment of genetic disease.

27 Apr 2010

MMC announces acquisition of BGR.com

Mail.com Media Corporation, the digital media company that owns and operates the Mail.com portal and email service as well as a growing portfolio of lifestyle brands including, Deadline.com, HollywoodLife.com, Movieline.com and OnCars.com, announced today its acquisition of BGR.com, one of the top mobile/gadget sites in the world.

27 Apr 2010

Universite de Montreal demographer offers prediction of boomer future

Baby boomers are retiring healthy, financially secure and with a desire to travel. According to Universit- de Montr-al demographer Jacques L-gar-, baby boomers will remain among the most self-reliant generations to reach their golden years.

27 Apr 2010

High levels of phosphate in sodas accelerate signs of aging

Here's another reason to kick the soda habit. New research published online in the FASEB Journal shows that high levels of phosphates may add more "pop" to sodas and processed foods than once thought. That's because researchers found that the high levels of phosphates accelerate signs of aging. High phosphate levels may also increase the prevalence and severity of age-related complications, such as chronic kidney disease and cardiovascular calcification, and can also induce severe muscle and skin atrophy.

27 Apr 2010

Medication-free home ventilation system designed to remove allergens

According to a recent report by USA Today, due to 2010's unusually cold winter temperatures, allergy sufferers are now poised to experience the worst pollen season in years, with pollen counts skyrocketing and sufferers hiding indoors to avoid exposure. Yet as allergens creep indoors, sufferers continue to cough, sneeze and seek relief. With the introduction of EZ Breathe, a new innovative home ventilation system designed to remove allergens and reduce indoor concentrations of pollen, allergy sufferers now have a medication-free solution.

27 Apr 2010

DNASTAR, Scarab Genomics announce launch of DNA and RNA sequencing services business

DNASTAR and Scarab Genomics, sister companies founded by genomics pioneer Fred Blattner, announce the launch of a next-generation DNA and RNA sequencing services business. Using their combined expertise, the companies will be offering a full range of sequencing services including library preparation, coordinating the most appropriate sequencing technology and platform, assembly, analysis, annotation, and visualization of end results.

27 Apr 2010

ICON reports net revenues of $219 million for first-quarter 2010

ICON, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today reported its financial results for the first quarter ended March 31, 2010.

27 Apr 2010

Prime-boost malaria vaccine regimen provides sterile protection: Vical

Vical Incorporated announced today that a prime-boost malaria vaccine regimen provided sterile protection, with no disease symptoms and no detectable malaria parasites, in 4 of 15 vaccinated volunteers a full 28 days after challenge with multiple infected-mosquito bites.

27 Apr 2010

Researchers to commence enrolling participants in National Children's Study

After years of planning, UT Southwestern Medical Center researchers are ready to begin enrolling participants in the National Children's Study, which will examine the effects of environmental and genetic factors on child and adult health.

27 Apr 2010

Protalix BioTherapeutics submits validation data for taliglucerase alfa manufacturing process to the FDA

Protalix BioTherapeutics, Inc., announced today it has submitted validation data regarding the Company's manufacturing process for taliglucerase alfa to the U.S. Food and Drug Administration (FDA). The Company made the submission in response to a request from the FDA for validation data from the Company's upgraded manufacturing facility. The FDA is currently reviewing the Company's New Drug Application (NDA) for taliglucerase alfa for the treatment of Gaucher disease.

27 Apr 2010

MicroStockProfit.com announces investment report featuring BioElectronics

MicroStockProfit.com announces an investment report featuring BioElectronics Corp. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

27 Apr 2010

UK MHRA authorizes Presidio Pharmaceuticals to initiate Phase 1 clinical trial of PPI-461 for HCV

Presidio Pharmaceuticals, Inc. announced today that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has authorized the initiation of a Phase 1 first-in-human clinical trial of PPI-461, an orally administered NS5A inhibitor for the treatment of hepatitis C virus (HCV). The Phase 1 clinical trial will be conducted in healthy volunteers.

27 Apr 2010

Ashland reports 13% increase in sales from $1,990M to $2,248M for second-quarter 2010

For its 2010 second quarter, Ashland reported sales of $2,248 million, operating income of $151 million and net income of $22 million (27 cents per share). Net income was favorably affected by $2 million aftertax (2 cents per share) from discontinued operations. Cash flows provided by operating activities from continuing operations amounted to $183 million.

27 Apr 2010

Kinetic Concepts' first-quarter 2010 total revenues increase 3% to $485.8M

Kinetic Concepts, Inc. today reported first quarter 2010 total revenue of $485.8 million, an increase of 3% from the first quarter of 2009. Foreign currency exchange movements favorably impacted total revenue for the first quarter of 2010 by 2% compared to the corresponding period of the prior year.

27 Apr 2010

Illumina announces shipment of HiScanSQ system for research needs

Illumina, Inc. today announced shipment of HiScanSQ, the first instrument to integrate microarray analysis and next-generation sequencing in a modular design that can evolve with changing research needs.

From Illumina, Inc. 27 Apr 2010

Centene's first-quarter Premium and Service Revenues up 12.5% to $1.022 billion

Centene Corporation today announced its financial results for the quarter ended March 31, 2010. The results of operations for our New Jersey health plan, University Health Plans, are classified as discontinued operations. The discussions below, with the exception of cash flow information, are in the context of continuing operations and all financial ratios exclude premium taxes.

27 Apr 2010

New DaVita Phosphorus Challenge tool for CKD and dialysis patients

DaVita Inc., a leading provider of kidney care services for those diagnosed with chronic kidney disease, today announced the launch of the DaVita Phosphorus Challenge, an online resource designed to serve as a core learning tool for CKD and dialysis patients.

27 Apr 2010

European commission's FP7 programme allocated euro 6.10 billion

Europe is moving towards becoming a knowledge-based economy. Keeping in line with this objective, the European commission has instituted the Framework 7 (FP7) programme. Launched to support the re-launched Lisbon strategy, FP7 focuses on research themes rather than the framework programmes of the past. It has been designed to meet some of the persisting challenges of raising Europe to match global excellence in research, thereby benefiting the European life science funding.

27 Apr 2010